Cambridge's Agios wins FDA approval for second cancer drug
July 20, 2018 at 14:46 PM EDT
"This is a shift in the entire treatment paradigm," Agios CEO David Schenkein told the Business Journal. "This is obviously a very exciting day for Agios, but even more so, for patients who now have a treatment that wasn't previously available."
